Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does VISMODEGIB Cause Chronic obstructive pulmonary disease? 12 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Chronic obstructive pulmonary disease have been filed in association with VISMODEGIB (ERIVEDGE). This represents 0.2% of all adverse event reports for VISMODEGIB.

12
Reports of Chronic obstructive pulmonary disease with VISMODEGIB
0.2%
of all VISMODEGIB reports
1
Deaths
4
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From VISMODEGIB?

Of the 12 reports, 1 (8.3%) resulted in death, 4 (33.3%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for VISMODEGIB. However, 12 reports have been filed with the FAERS database.

What Other Side Effects Does VISMODEGIB Cause?

Muscle spasms (1,937) Alopecia (1,330) Ageusia (958) Fatigue (899) Dysgeusia (706) Weight decreased (688) Nausea (669) Decreased appetite (662) Death (657) Diarrhoea (446)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which VISMODEGIB Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

VISMODEGIB vs VITAMIN A VISMODEGIB vs VITAMIN B VISMODEGIB vs VITAMIN D NOS VISMODEGIB vs VITAMINS VISMODEGIB vs VOCLOSPORIN

Related Pages

VISMODEGIB Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease VISMODEGIB Demographics